International Journal of Endocrinology / 2013 / Article / Tab 3

Clinical Study

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)

Table 3

Changes in biochemical measurements.

ParametersGroup0 month12 monthsP-valueDifferenceP-value

Aspartate aminotransferase (IU/L)T 0.583
L >0.999 0.672
Alanine aminotransferase (IU/L)T 0.261
L 0.344 0.672
γ Glutamyl transpeptidase (IU/L)T 0.683
L 0.463 0.471
Total cholesterol (mg/dL)T 0.505
L 0.345 0.525
Triglyceride (mg/dL)T 0.433
L 0.866 0.899
HDL cholesterol (mg/dL)T 0.283
L 0.343 >0.999
Free fatty acids (mEq/L)T 0.005
L 0.237 0.007
Fasting plasma glucose (mg/dL)T 0.247
L 0.078 0.031
IRI (μU/mL)T 0.720
L 0.498 0.396
Hemoglobin A1c (%)T 0.552
L 0.017 0.001
HOMA-IRT >0.999
L 0.686 0.770
HOMA-βT 0.374
L 0.043 0.062
Creatinine (mg/dL)T 0.149
L 0.655 0.274
Uric acid (mg/dL)T 0.016
L 0.046 0.002
Primary bile acids (μmol/L)T 0.534
L 0.345 0.447
Secondary bile acids (μmol/L)T 0.906
L 0.735 0.554
Microalbumin in urine (μg/mL)T 0.173
L 0.173 0.884

Data are presented as mean SD. Parameters at 0 and 12 months of treatment were compared by Wilcoxon's matched-pair signed-rank test. Differences are shown as [value at 12 months − value at 0 month]. Differences between groups (telmisartan (T) versus losartan (L)) were compared by Mann-Whitney test.
HDL: high-density lipoprotein, IRI: immunoreactive insulin, and HOMA-IR: homeostasis model assessment-insulin resistance.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.